Standard

Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. / Shinkai, Yasuhiro; Kashihara, Shinichi; Minematsu, Go et al.

In: Nucleic Acid Therapeutics, Vol. 27, No. 3, 06.2017, p. 168-175.

Research output: Contribution to journal › Article › peer-review

Harvard

Shinkai, Y, Kashihara, S, Minematsu, G, Fujii, H, Naemura, M, Kotake, Y, Morita, Y, Ohnuki, K, Fokina, AA, Stetsenko, DA, Filichev, VV & Fujii, M 2017, 'Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates', Nucleic Acid Therapeutics, vol. 27, no. 3, pp. 168-175. https://doi.org/10.1089/nat.2016.0647

APA

Shinkai, Y., Kashihara, S., Minematsu, G., Fujii, H., Naemura, M., Kotake, Y., Morita, Y., Ohnuki, K., Fokina, A. A., Stetsenko, D. A., Filichev, V. V., & Fujii, M. (2017). Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. Nucleic Acid Therapeutics, 27(3), 168-175. https://doi.org/10.1089/nat.2016.0647

Vancouver

Shinkai Y, Kashihara S, Minematsu G, Fujii H, Naemura M, Kotake Y et al. Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. Nucleic Acid Therapeutics. 2017 Jun;27(3):168-175. doi: 10.1089/nat.2016.0647

Author

Shinkai, Yasuhiro ; Kashihara, Shinichi ; Minematsu, Go et al. / Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates. In: Nucleic Acid Therapeutics. 2017 ; Vol. 27, No. 3. pp. 168-175.

BibTeX

@article{c0cb298e3fd4432cb3ba11fd7d4c6d3e,
title = "Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates",
abstract = "Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling and the application of them to silencing of bcr/abl chimeric gene in human chronic myelogenous leukemia cell line K562. Two types of siRNA-NES conjugates were prepared, and both sense strands at 5′ ends were covalently linked to a NES peptide derived from TFIIIA and HIV-1 REV, respectively. Significant enhancement of silencing efficiency was observed for both of them. siRNA-TFIIIA NES conjugate suppressed the expression of BCR/ABL gene to 8.3% at 200 nM and 11.6% at 50 nM, and siRNA-HIV-1REV NES conjugate suppressed to 4.0% at 200 nM and 6.3% at 50 nM, whereas native siRNA suppressed to 36.3% at 200 nM and 30.2% at 50 nM. We could also show complex of siRNA-NES conjugate and designed amphiphilic peptide peptideβ7 could be taken up into cells with no cytotoxicity and showed excellent silencing efficiency. We believe that the complex siRNA-NES conjugate and peptideβ7 is a promising candidate for in vivo use and therapeutic applications.",
keywords = "BCR/ABL, SiRNA-NES conjugates, SPFC, siRNA-NES conjugates, TRANSCRIPTION FACTOR, OLIGONUCLEOTIDES",
author = "Yasuhiro Shinkai and Shinichi Kashihara and Go Minematsu and Hirofumi Fujii and Madoka Naemura and Yojiro Kotake and Yasutaka Morita and Koichiro Ohnuki and Fokina, {Alesya A.} and Stetsenko, {Dmitry A.} and Filichev, {Vyacheslav V.} and Masayuki Fujii",
note = "Funding Information: This work was financially supported by JSPS KAKEN grant number 22550159. D.A.S. is supported by RSF grant no. 14-44-00068. A.A.F. acknowledges support from RFBR grant no. 16-03-01055. Publisher Copyright: {\textcopyright} 2017, Mary Ann Liebert, Inc. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2017",
month = jun,
doi = "10.1089/nat.2016.0647",
language = "English",
volume = "27",
pages = "168--175",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates

AU - Shinkai, Yasuhiro

AU - Kashihara, Shinichi

AU - Minematsu, Go

AU - Fujii, Hirofumi

AU - Naemura, Madoka

AU - Kotake, Yojiro

AU - Morita, Yasutaka

AU - Ohnuki, Koichiro

AU - Fokina, Alesya A.

AU - Stetsenko, Dmitry A.

AU - Filichev, Vyacheslav V.

AU - Fujii, Masayuki

N1 - Funding Information: This work was financially supported by JSPS KAKEN grant number 22550159. D.A.S. is supported by RSF grant no. 14-44-00068. A.A.F. acknowledges support from RFBR grant no. 16-03-01055. Publisher Copyright: © 2017, Mary Ann Liebert, Inc. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2017/6

Y1 - 2017/6

N2 - Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling and the application of them to silencing of bcr/abl chimeric gene in human chronic myelogenous leukemia cell line K562. Two types of siRNA-NES conjugates were prepared, and both sense strands at 5′ ends were covalently linked to a NES peptide derived from TFIIIA and HIV-1 REV, respectively. Significant enhancement of silencing efficiency was observed for both of them. siRNA-TFIIIA NES conjugate suppressed the expression of BCR/ABL gene to 8.3% at 200 nM and 11.6% at 50 nM, and siRNA-HIV-1REV NES conjugate suppressed to 4.0% at 200 nM and 6.3% at 50 nM, whereas native siRNA suppressed to 36.3% at 200 nM and 30.2% at 50 nM. We could also show complex of siRNA-NES conjugate and designed amphiphilic peptide peptideβ7 could be taken up into cells with no cytotoxicity and showed excellent silencing efficiency. We believe that the complex siRNA-NES conjugate and peptideβ7 is a promising candidate for in vivo use and therapeutic applications.

AB - Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling and the application of them to silencing of bcr/abl chimeric gene in human chronic myelogenous leukemia cell line K562. Two types of siRNA-NES conjugates were prepared, and both sense strands at 5′ ends were covalently linked to a NES peptide derived from TFIIIA and HIV-1 REV, respectively. Significant enhancement of silencing efficiency was observed for both of them. siRNA-TFIIIA NES conjugate suppressed the expression of BCR/ABL gene to 8.3% at 200 nM and 11.6% at 50 nM, and siRNA-HIV-1REV NES conjugate suppressed to 4.0% at 200 nM and 6.3% at 50 nM, whereas native siRNA suppressed to 36.3% at 200 nM and 30.2% at 50 nM. We could also show complex of siRNA-NES conjugate and designed amphiphilic peptide peptideβ7 could be taken up into cells with no cytotoxicity and showed excellent silencing efficiency. We believe that the complex siRNA-NES conjugate and peptideβ7 is a promising candidate for in vivo use and therapeutic applications.

KW - BCR/ABL

KW - SiRNA-NES conjugates

KW - SPFC

KW - siRNA-NES conjugates

KW - TRANSCRIPTION FACTOR

KW - OLIGONUCLEOTIDES

UR - http://www.scopus.com/inward/record.url?scp=85020229513&partnerID=8YFLogxK

U2 - 10.1089/nat.2016.0647

DO - 10.1089/nat.2016.0647

M3 - Article

C2 - 28355131

AN - SCOPUS:85020229513

VL - 27

SP - 168

EP - 175

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 3

ER -

ID: 26016240